Wells Fargo Downgrades Myriad Genetics (MYGN) to Market Perform
Tweet
Share
E-mailGet Alerts MYGN Hot Sheet
Price: $4.52 +0.44%
Rating Summary:
7 Buy, 19 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 13 | New: 23
Rating Summary:
7 Buy, 19 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 13 | New: 23
Join SI Premium – FREE
Wells Fargo downgraded Myriad Genetics (NASDAQ: MYGN) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.
Shares of Myriad Genetics closed at $29.46 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wells Fargo Downgrades Ross Stores, Inc. (ROST) to Equal Weight
- Guggenheim Downgrades Apogee Therapeutics Inc (APGE) to Neutral
- Wolfe Research Downgrades Five Below (FIVE) to Peerperform
Create E-mail Alert Related Categories
DowngradesRelated Entities
Wells FargoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
